Lobular breast carcinoma and its variants

Seminars in Diagnostic Pathology

Volumn 27, Issue 1, 2010, Pages 49-61

  Rakha, Emad A ^a   Ellis, Ian O ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Behavior; Breast cancer; Lobular carcinoma; Precursor lesions; Variants

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; UVOMORULIN;

ARTICLE; ATYPICAL LOBULAR HYPERPLASIA; BREAST CARCINOMA; CANCER GRADING; CANCER RISK; CANCER STAGING; CARCINOMA IN SITU; CHROMOSOME 16Q; CHROMOSOME LOSS; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE LOBULAR CARCINOMA; LOBULAR CARCINOMA IN SITU; LOBULAR INTRAEPITHELIAL NEOPLASIA; MALIGNANT TRANSFORMATION; MAMMOGRAPHY; NEEDLE BIOPSY; PRECANCER; PRIORITY JOURNAL;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; CHROMOSOME ABERRATIONS; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; NEOPLASM INVASIVENESS; TREATMENT OUTCOME;

EID: 77349102986     PISSN: 07402570     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semdp.2009.12.009     Document Type: Article

References (159)

1. Foote F.W., Stewart F.W. Lobular carcinoma in situ. A rare form of mammary cancer. Am J Pathol 1941, 17:491-496.
2. Wheeler J.E., Enterline H.T. Lobular carcinoma of the breast in situ and infiltrating. Pathol Annu 1976, 11:161-188.
3. Dunnwald L.K., Rossing M.A., Li C.I. Hormone receptor status, tumor characteristics, and prognosis: A prospective cohort of breast cancer patients. Breast Cancer Res 2007, 9:R6.
4. Li C.I., Uribe D.J., Daling J.R. Clinical characteristics of different histologic types of breast cancer. Br J Cancer 2005, 93:1046-1052.
5. Rakha E.A., El-Sayed M.E., Powe D.G., et al. Invasive lobular carcinoma of the breast: Response to hormonal therapy and outcomes. Eur J Cancer 2008, 44:73-83.
6. Arpino G., Bardou V.J., Clark G.M., et al. Infiltrating lobular carcinoma of the breast: Tumor characteristics and clinical outcome. Breast Cancer Res 2004, 6:R149-R156.
7. Henson D., Tarone R. A study of lobular carcinoma of the breast based on the third national cancer survey in the United States of America. Tumori 1979, 65:133-142.
8. Li C.I., Anderson B.O., Daling J.R., et al. Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 2003, 289:1421-1424.
9. Li C.I., Anderson B.O., Porter P., et al. Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer 2000, 88:2561-2569.
10. Bonnier P., Romain S., Giacalone P.L., et al. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 1995, 85:11-17.
11. Li C.I., Daling J.R., Malone K.E., et al. Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2006, 15:946-954.
12. Rakha E.A., Gill M.S., El-Sayed M.E., et al. The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morphology. Breast Cancer Res Treat 2008, 114:243-250.
13. Martinez V., Azzopardi J.G. Invasive lobular carcinoma of the breast: Incidence and variants. Histopathology 1979, 3:467-488.
14. Cleton-Jansen A.M. E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: Different genetic pathways in ductal and lobular breast cancer?. Breast Cancer Res 2002, 4:5-8.
15. Stange D.E., Radlwimmer B., Schubert F., et al. High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer. Clin Cancer Res 2006, 12:345-352.
16. Weigelt B., Geyer F.C., Natrajan R., et al. The molecular underpinning of lobular histological growth pattern: A genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol 2010, 220:45-57.
17. Shelley Hwang E., Nyante S.J., Yi Chen Y., et al. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer 2004, 100:2562-2572.
18. Loo L.W., Grove D.I., Williams E.M., et al. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 2004, 64:8541-8549.
19. Domagala W., Markiewski M., Kubiak R., et al. Immunohistochemical profile of invasive lobular carcinoma of the breast: Predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive. Virchows Arch A Pathol Anat Histopathol 1993, 423:497-502.
20. Sastre-Garau X., Jouve M., Asselain B., et al. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 1996, 77:113-120.
21. Rakha E.A., El-Sayed M.E., Menon S., et al. Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res Treat 2008, 111:121-127.
22. Wheeler D.T., Tai L.H., Bratthauer G.L., et al. Tubulolobular carcinoma of the breast: An analysis of 27 cases of a tumor with a hybrid morphology and immunoprofile. Am J Surg Pathol 2004, 28:1587-1593.
23. Hanby A.M., Hughes T.A. In situ and invasive lobular neoplasia of the breast. Histopathology 2008, 52:58-66.
24. El-Sayed M.E., Rakha E.A., Reed J., et al. Predictive value of needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening. Histopathology 2008, 53:650-657.
25. Beute B.J., Kalisher L., Hutter R.V. Lobular carcinoma in situ of the breast: Clinical, pathologic, and mammographic features. AJR Am J Roentgenol 1991, 157:257-265.
26. Menon S., Porter G.J., Evans A.J., et al. The significance of lobular neoplasia on needle core biopsy of the breast. Virchows Arch 2008, 452:473-479.
27. Georgian-Smith D., Lawton T.J. Calcifications of lobular carcinoma in situ of the breast: Radiologic-pathologic correlation. AJR Am J Roentgenol 2001, 176:1255-1259.
28. Abdel-Fatah T.M., Powe D.G., Hodi Z., et al. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: Further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol 2008, 32:513-523.
29. Abdel-Fatah T.M., Powe D.G., Hodi Z., et al. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol 2007, 31:417-426.
30. Leibl S., Regitnig P., Moinfar F. Flat epithelial atypia (DIN 1a, atypical columnar change): An underdiagnosed entity very frequently coexisting with lobular neoplasia. Histopathology 2007, 50:859-865.
31. Lakhani S.R. In-situ lobular neoplasia: Time for an awakening. Lancet 2003, 361:96.
32. Renshaw A.A., Cartagena N., Derhagopian R.P., et al. Lobular neoplasia in breast core needle biopsy specimens is not associated with an increased risk of ductal carcinoma in situ or invasive carcinoma. Am J Clin Pathol 2002, 117:797-799.
33. Simpson P.T., Gale T., Fulford L.G., et al. The diagnosis and management of pre-invasive breast disease: Pathology of atypical lobular hyperplasia and lobular carcinoma in situ. Breast Cancer Res 2003, 5:258-262.
34. Marshall L.M., Hunter D.J., Connolly J.L., et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev 1997, 6:297-301.
35. Page D.L., Schuyler P.A., Dupont W.D., et al. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: A retrospective cohort study. Lancet 2003, 361:125-129.
36. Haagensen C.D., Lane N., Lattes R., et al. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 1978, 42:737-769.
37. Warnberg F., Yuen J., Holmberg L. Risk of subsequent invasive breast cancer after breast carcinoma in situ. Lancet 2000, 355:724-725.
38. Li C.I., Malone K.E., Saltzman B.S., et al. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer 2006, 106:2104-2112.
39. Fisher E.R., Land S.R., Fisher B., et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Twelve-year observations concerning lobular carcinoma in situ. Cancer 2004, 100:238-244.
40. Hwang H., Barke L.D., Mendelson E.B., et al. Atypical lobular hyperplasia and classic lobular carcinoma in situ in core biopsy specimens: Routine excision is not necessary. Mod Pathol 2008, 21:1208-1216.
41. Rudloff U., Brogi E., Brockway J.P., et al. Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer 2009, 115:1203-1214.
42. Middleton L.P., Grant S., Stephens T., et al. Lobular carcinoma in situ diagnosed by core needle biopsy: When should it be excised?. Mod Pathol 2003, 16:120-129.
43. Lakhani S.R., Audretsch W., Cleton-Jensen A.M., et al. The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)?. Eur J Cancer 2006, 42:2205-2211.
44. Hwang E.S., Nyante S.J., Yi Chen Y., et al. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer 2004, 100:2562-2572.
45. Lehr H.A., Folpe A., Yaziji H., et al. Cytokeratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma. Am J Clin Pathol 2000, 114:190-196.
46. Jacobs T.W., Pliss N., Kouria G., et al. Carcinomas in situ of the breast with indeterminate features: Role of E-cadherin staining in categorization. Am J Surg Pathol 2001, 25:229-236.
47. Simpson P.T., Reis-Filho J.S., Lambros M.B., et al. Molecular profiling pleomorphic lobular carcinomas of the breast: Evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol 2008, 215:231-244.
48. European Guidelines for Quality Assurance in Mammography Screening 2006, Office for Official Publications of the European Communities, Luxembourg. 4th ed. N.M. Perry, M. Broeders, C.J.M. de Wolf (Eds.).
49. Guidelines for Non-Operative Diagnostic Procedures and Reporting in Breast Cancer Screening 2001, NHSBSP Breast Screening Programme, NHSBSP Breast Screening Programme, Sheffield, United Kingdom, NHSBSP Pub. No 50.
50. Fadare O., Dadmanesh F., Alvarado-Cabrero I., et al. Lobular intraepithelial neoplasia [lobular carcinoma in situ] with comedo-type necrosis: A clinicopathologic study of 18 cases. Am J Surg Pathol 2006, 30:1445-1453.
51. Ciocca R.M., Li T., Freedman G.M., et al. Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy. Ann Surg Oncol 2008, 15:2263-2271.
52. Pathology reporting of breast disease. A Joint Document Incorporating the Third Edition of the NHS Breast Screening Programme's Guidelines for Pathology Reporting in Breast Cancer Screening and the Second Edition of The Royal College of Pathologists' Minimum Dataset for Breast Cancer Histopathology 2005, NHS Cancer Screening Programmes and The Royal College of Pathologists, Sheffield, United Kingdom.
53. Howat A.J., Armour A., Ellis I.O. Microinvasive lobular carcinoma of the breast. Histopathology 2000, 37:477-478.
54. Toikkanen S., Pylkkanen L., Joensuu H. Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer 1997, 76:1234-1240.
55. Evans W.P., Warren Burhenne L.J., Laurie L., et al. Invasive lobular carcinoma of the breast: Mammographic characteristics and computer-aided detection. Radiology 2002, 225:182-189.
56. Cornford E.J., Wilson A.R., Athanassiou E., et al. Mammographic features of invasive lobular and invasive ductal carcinoma of the breast: A comparative analysis. Br J Radiol 1995, 68:450-453.
57. Silverstein M.J., Lewinsky B.S., Waisman J.R., et al. Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma?. Cancer 1994, 73:1673-1677.
58. Broet P., de la Rochefordiere A., Scholl S.M., et al. Contralateral breast cancer: Annual incidence and risk parameters. J Clin Oncol 1995, 13:1578-1583.
59. Berg W.A., Gutierrez L., NessAiver M.S., et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology 2004, 233:830-849.
60. Uchiyama N., Miyakawa K., Moriyama N., et al. Radiographic features of invasive lobular carcinoma of the breast. Radiat Med 2001, 19:19-25.
61. Kepple J., Layeeque R., Klimberg V.S., et al. Correlation of magnetic resonance imaging and pathologic size of infiltrating lobular carcinoma of the breast. Am J Surg 2005, 190:623-627.
62. Moore M.M., Borossa G., Imbrie J.Z., et al. Association of infiltrating lobular carcinoma with positive surgical margins after breast-conservation therapy. Ann Surg 2000, 231:877-882.
63. Mann RM, Loo CE, Wobbes T, et al: The impact of preoperative breast MRI on the re-excision rate in invasive lobular carcinoma of the breast. Breast Cancer Res Treat (in press).
64. Hwang S., Ioffe O., Lee I., et al. Cytologic diagnosis of invasive lobular carcinoma: Factors associated with negative and equivocal diagnoses. Diagn Cytopathol 2004, 31:87-93.
65. Tan S.M., Behranwala K.A., Trott P.A., et al. A retrospective study comparing the individual modalities of triple assessment in the pre-operative diagnosis of invasive lobular breast carcinoma. Eur J Surg Oncol 2002, 28:203-208.
66. Cariaggi M.P., Bulgaresi P., Confortini M., et al. Analysis of the causes of false negative cytology reports on breast cancer fine needle aspirates. Cytopathology 1995, 6:156-161.
67. Wellings S.R., Jensen H.M., Marcum R.G. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 1975, 55:231-273.
68. Yoder B.J., Wilkinson E.J., Massoll N.A. Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast. Breast J 2007, 13:172-179.
69. Dixon J.M., Anderson T.J., Page D.L., et al. Infiltrating lobular carcinoma of the breast. Histopathology 1982, 6:149-161.
70. Korkola J.E., DeVries S., Fridlyand J., et al. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 2003, 63:7167-7175.
71. Cristofanilli M., Gonzalez-Angulo A., Sneige N., et al. Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes. J Clin Oncol 2005, 23:41-48.
72. du Toit R.S., Locker A.P., Ellis I.O., et al. An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncol 1991, 17:251-257.
73. du Toit R.S., Locker A.P., Ellis I.O., et al. Invasive lobular carcinomas of the breast-The prognosis of histopathological subtypes. Br J Cancer 1989, 60:605-609.
74. WHO Classification of Tumours: Pathology and Genetics 2003, IARC press, Lyon, France.
75. Newman W. Lobular carcinoma of the female breast. Report of 73 cases. Ann Surg 1966, 164:305-314.
76. DiCostanzo D., Rosen P.P., Gareen I., et al. Prognosis in infiltrating lobular carcinoma. An analysis of "classical" and variant tumors. Am J Surg Pathol 1990, 14:12-23.
77. Eusebi V., Magalhaes F., Azzopardi J.G. Pleomorphic lobular carcinoma of the breast: An aggressive tumor showing apocrine differentiation. Hum Pathol 1992, 23:655-662.
78. Middleton L.P., Palacios D.M., Bryant B.R., et al. Pleomorphic lobular carcinoma: Morphology, immunohistochemistry, and molecular analysis. Am J Surg Pathol 2000, 24:1650-1656.
79. Fisher E.R., Gregorio R.M., Redmond C., et al. Tubulolobular invasive breast cancer: A variant of lobular invasive cancer. Hum Pathol 1977, 8:679-683.
80. Orvieto E., Maiorano E., Bottiglieri L., et al. Clinicopathologic characteristics of invasive lobular carcinoma of the breast: Results of an analysis of 530 cases from a single institution. Cancer 2008, 113:1511-1520.
81. Roberts M.M., Alexander F.E., Anderson T.J., et al. Edinburgh trial of screening for breast cancer: Mortality at seven years. Lancet 1990, 335:241-246.
82. Ladekarl M., Sorensen F.B. Prognostic, quantitative histopathologic variables in lobular carcinoma of the breast. Cancer 1993, 72:2602-2611.
83. Sinha P.S., Bendall S., Bates T. Does routine grading of invasive lobular cancer of the breast have the same prognostic significance as for ductal cancers?. Eur J Surg Oncol 2000, 26:733-737.
84. Talman M.L., Jensen M.B., Rank F. Invasive lobular breast cancer. Prognostic significance of histological malignancy grading. Acta Oncol 2007, 46:803-809.
85. Pereira H., Pinder S.E., Sibbering D.M., et al. Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 1995, 27:219-226.
86. Sinn H.P., Kellerhoff N.M., Kellerhoff R., et al. Subtyping and prognostic assessment of invasive lobular breast carcinoma. Pathologe 1997, 18:37-44.
87. Moreno-Elola A., Aguilar A., Roman J.M., et al. Prognostic factors in invasive lobular carcinoma of the breast: A multivariate analysis. A multicentre study after seventeen years of follow-up. Ann Chir Gynaecol 1999, 88:252-258.
88. Bane A.L., Tjan S., Parkes R.K., et al. Invasive lobular carcinoma: To grade or not to grade. Mod Pathol 2005, 18:621-628.
89. Mokbel K. Grading of infiltrating lobular carcinoma. Eur J Surg Oncol 2001, 27:609-610.
90. Paumier A., Sagan C., Campion L., et al. Accuracy of conservative treatment for infiltrating lobular breast cancer: A retrospective study of 217 infiltrating lobular carcinomas and 2155 infiltrating ductal carcinomas. J Gynecol Obstet Biol Reprod (Paris) 2003, 32:529-534.
91. Zafrani B., Aubriot M.H., Mouret E., et al. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: Comparison with biochemical determination in a prospective study of 793 cases. Histopathology 2000, 37:536-545.
92. Nadji M., Gomez-Fernandez C., Ganjei-Azar P., et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: Experience with 5,993 breast cancers. Am J Clin Pathol 2005, 123:21-27.
93. Radhi J.M. Immunohistochemical analysis of pleomorphic lobular carcinoma: Higher expression of p53 and chromogranin and lower expression of ER and PgR. Histopathology 2000, 36:156-160.
94. Rozan S., Vincent-Salomon A., Zafrani B., et al. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 1998, 79:27-33.
95. Soomro S., Shousha S., Taylor P., et al. c-erbB-2 expression in different histological types of invasive breast carcinoma. J Clin Pathol 1991, 44:211-214.
96. Mazoujian G., Bodian C., Haagensen D.E., et al. Expression of GCDFP-15 in breast carcinomas. Relationship to pathologic and clinical factors. Cancer 1989, 63:2156-2161.
97. Oyama T., Kashiwabara K., Yoshimoto K., et al. Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. Cancer Res 1998, 58:2876-2880.
98. Mathieu M.C., Rouzier R., Llombart-Cussac A., et al. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 2004, 40:342-351.
99. Bratthauer G.L., Moinfar F., Stamatakos M.D., et al. Combined E-cadherin and high molecular weight cytokeratin immunoprofile differentiates lobular, ductal, and hybrid mammary intraepithelial neoplasias. Hum Pathol 2002, 33:620-627.
100. Roylance R., Gorman P., Papior T., et al. A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH. Oncogene 2006, 25:6544-6553.
101. Rakha E.A., Green A.R., Powe D.G., et al. Chromosome 16 tumor-suppressor genes in breast cancer. Genes Chromosomes Cancer 2006, 45:527-535.
102. Moll R., Mitze M., Frixen U.H., et al. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol 1993, 143:1731-1742.
103. Gamallo C., Palacios J., Suarez A., et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol 1993, 142:987-993.
104. Berx G., Cleton-Jansen A.M., Strumane K., et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996, 13:1919-1925.
105. De Leeuw W.J., Berx G., Vos C.B., et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 1997, 183:404-411.
106. Sarrio D., Perez-Mies B., Hardisson D., et al. Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene 2004, 23:3272-3283.
107. Strathdee G. Epigenetic versus genetic alterations in the inactivation of E-cadherin. Semin Cancer Biol 2002, 12:373-379.
108. Lei H., Sjoberg-Margolin S., Salahshor S., et al. CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk. Int J Cancer 2002, 98:199-204.
109. Berx G., Cleton-Jansen A.M., Nollet F., et al. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995, 14:6107-6115.
110. Acs G., Lawton T.J., Rebbeck T.R., et al. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 2001, 115:85-98.
111. Goldstein N.S., Bassi D., Watts J.C., et al. E-cadherin reactivity of 95 noninvasive ductal and lobular lesions of the breast. Implications for the interpretation of problematic lesions. Am J Clin Pathol 2001, 115:534-542.
112. Goldstein N.S., Kestin L.L., Vicini F.A. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast. Cancer 2001, 92:738-747.
113. Droufakou S., Deshmane V., Roylance R., et al. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer 2001, 92:404-408.
114. Yoshiura K., Kanai Y., Ochiai A., et al. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci U S A 1995, 92:7416-7419.
115. Batlle E., Sancho E., Franci C., et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000, 2:84-89.
116. Vos C.B., Cleton-Jansen A.M., Berx G., et al. E-cadherin inactivation in lobular carcinoma in situ of the breast: An early event in tumorigenesis. Br J Cancer 1997, 76:1131-1133.
117. Mastracci T.L., Tjan S., Bane A.L., et al. E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast. Mod Pathol 2005, 18:741-751.
118. Reis-Filho J.S., Cancela Paredes J., Milanezi F., et al. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast. Cancer 2002, 94:2114-2115. discussion 2115-2116.
119. Asgeirsson K.S., Jo J.G., Tryggvadottir L., et al. Altered expression of E-cadherin in breast cancer. Patterns, mechanisms and clinical significance. Eur J Cancer 2000, 36:1098-1106.
120. Goldstein N.S. Does the level of E-cadherin expression correlate with the primary breast carcinoma infiltration pattern and type of systemic metastases?. Am J Clin Pathol 2002, 118:425-434.
121. Da Silva L., Parry S., Reid L., et al. Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol 2008, 32:773-783.
122. Flagiello D., Gerbault-Seureau M., Padoy E., et al. Near haploidy in breast cancer: A particular pathway of chromosome evolution. Cancer Genet Cytogenet 1998, 102:54-58.
123. Nishizaki T., Chew K., Chu L., et al. Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer 1997, 74:513-517.
124. Bertucci F., Orsetti B., Negre V., et al. Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene 2008, 27:5359-5372.
125. Turashvili G., Bouchal J., Baumforth K., et al. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 2007, 7:55.
126. Berx G., Becker K.F., Hofler H., et al. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 1998, 12:226-237.
127. Keller G., Vogelsang H., Becker I., et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol 1999, 155:337-342.
128. Chan J.K., Wong C.S. Loss of E-cadherin is the fundamental defect in diffuse-type gastric carcinoma and infiltrating lobular carcinoma of the breast. Adv Anat Pathol 2001, 8:165-172.
129. Jacquemier J., Eisinger F., Nogues C., et al. Histological type and syncytial growth pattern affect E-cadherin expression in a multifactorial analysis of a combined panel of sporadic and BRCA1-associated breast cancers. Int J Cancer 1999, 83:45-49.
130. Weigelt B., Horlings H., Kreike B., et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008, 216:141-150.
131. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
132. Ashikari R., Huvos A.G., Urban J.A., et al. Infiltrating lobular carcinoma of the breast. Cancer 1973, 31:110-116.
133. Mate T.P., Carter D., Fischer D.B., et al. A clinical and histopathologic analysis of the results of conservation surgery and radiation therapy in stage I and II breast carcinoma. Cancer 1986, 58:1995-2002.
134. Santiago R.J., Harris E.E., Qin L., et al. Similar long-term results of breast-conservation treatment for stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast: The University of Pennsylvania experience. Cancer 2005, 103:2447-2454.
135. Vo T.N., Meric-Bernstam F., Yi M., et al. Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am J Surg 2006, 192:552-555.
136. Molland J.G., Donnellan M., Janu N.C., et al. Infiltrating lobular carcinoma-A comparison of diagnosis, management and outcome with infiltrating duct carcinoma. Breast 2004, 13:389-396.
137. Korhonen T., Huhtala H., Holli K. A comparison of the biological and clinical features of invasive lobular and ductal carcinomas of the breast. Breast Cancer Res Treat 2004, 85:23-29.
138. Casolo P., Raspadori A., Drei B., et al. Natural history of breast cancer: Lobular carcinoma versus ductal carcinoma in our experience. Ann Ital Chir 1997, 68:43-47. discussion 48.
139. Peiro G., Bornstein B.A., Connolly J.L., et al. The influence of infiltrating lobular carcinoma on the outcome of patients treated with breast-conserving surgery and radiation therapy. Breast Cancer Res Treat 2000, 59:49-54.
140. Schrenk P., Konstantiniuk P., Wölfl S., et al. Intraoperative frozen section examination of the sentinel lymph node in breast cancer. Rozhl Chir 2005, 84:217-222.
141. Hess K.R., Pusztai L., Buzdar A.U., et al. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 2003, 78:105-118.
142. Bouvet M., Ollila D.W., Hunt K.K., et al. Role of conservation therapy for invasive lobular carcinoma of the breast. Ann Surg Oncol 1997, 4:650-654.
143. Cocquyt V., Van Belle S. Lobular carcinoma in situ and invasive lobular cancer of the breast. Curr Opin Obstet Gynecol 2005, 17:55-60.
144. Tovey S.M., Brown S., Doughty J.C., et al. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer 2009, 100:680-683.
145. Shousha S., Backhous C.M., Alaghband-Zadeh J., et al. Alveolar variant of invasive lobular carcinoma of the breast. A tumor rich in estrogen receptors. Am J Clin Pathol 1986, 85:1-5.
146. Buchanan C.L., Flynn L.W., Murray M.P., et al. Is pleomorphic lobular carcinoma really a distinct clinical entity?. J Surg Oncol 2008, 98:314-317.
147. Ferlicot S., Vincent-Salomon A., Medioni J., et al. Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur J Cancer 2004, 40:336-341.
148. Winston C.B., Hadar O., Teitcher J.B., et al. Metastatic lobular carcinoma of the breast: Patterns of spread in the chest, abdomen, and pelvis on CT. AJR Am J Roentgenol 2000, 175:795-800.
149. Borst M.J., Ingold J.A. Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery 1993, 114:637-641. discussion 641-632.
150. Lamovec J., Bracko M. Metastatic pattern of infiltrating lobular carcinoma of the breast: An autopsy study. J Surg Oncol 1991, 48:28-33.
151. Jimeno A., Amador M.L., Gonzalez-Cortijo L., et al. Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma. Cancer 2004, 100:1833-1842.
152. Tubiana-Hulin M., Stevens D., Lasry S., et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: A retrospective study on 860 patients from one institution. Ann Oncol 2006, 17:1228-1233.
153. Wenzel C., Bartsch R., Hussian D., et al. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF. Breast Cancer Res Treat 2007, 104:109-114.
154. Katz A., Saad E.D., Porter P., et al. Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol 2007, 8:55-62.
155. Cocquyt V.F., Blondeel P.N., Depypere H.T., et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol 2003, 29:361-367.
156. Horobin J.M., Preece P.E., Dewar J.A., et al. Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg 1991, 78:213-217.
157. Dixon J.M., Jackson J., Renshaw L., et al. Neoadjuvant tamoxifen and aromatase inhibitors: Comparisons and clinical outcomes. J Steroid Biochem Mol Biol 2003, 86:295-299.
158. Dixon J.M., Anderson T.J., Page D.L., et al. Infiltrating lobular carcinoma of the breast: An evaluation of the incidence and consequence of bilateral disease. Br J Surg 1983, 70:513-516.
159. Davis R.P., Nora P.F., Kooy R.G., et al. Experience with lobular carcinoma of the breast. Emphasis on recent aspects of management. Arch Surg 1979, 114:485-488.